BRIANA LUXEM: Open Payments
NPI 1396578183 · CHARLESTON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$669 in 34 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $272 · 2025 $669
Food & beverage: $669
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 4 | $80 |
| ABBVIE INC. | 4 | $78 |
| Novo Nordisk Inc | 3 | $60 |
| Exact Sciences Corporation | 3 | $58 |
| AstraZeneca Pharmaceuticals LP | 3 | $53 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $48 |
| Astellas Pharma US Inc | 2 | $48 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $45 |
| SHIELD THERAPEUTICS INC | 2 | $45 |
| PFIZER INC. | 2 | $42 |
Products named: VRAYLAR, FARXIGA, CAPLYTA, Veozah, Kerendia, ACCRUFER, MOUNJARO, ELIQUIS.
Industry payments across SC — which companies pay providers there.
